Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 54Lung Neoplasms 42Adenocarcinoma of Lung 8Neoplasm Metastasis 6Adenocarcinoma, Bronchiolo-Alveolar 4Melanoma 3Carcinoma, Renal Cell 3Brain Neoplasms 3Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Neoplasms 2Mesothelioma, Malignant 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Carcinoma 2Breast Neoplasms 2Unresectable Stage III NSCLC 1Thymus Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pleural Effusion, Malignant 1Pain 1Ovarian Neoplasms 1Mesothelioma 1Lung Cancer Metastatic 1Liposarcoma, Myxoid 1

Interventions

Bronchoscopy 2X-Rays 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1Carboplatin 1Bevacizumab 1Argon Plasma Coagulation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemoptysis × Radiation × Thoracic × Clear all
NCT00387374 2013-01-17

Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

National Cancer Institute (NCI)

Phase 2 Completed
72 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hemoptysis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡